// App-Quantinova.ai

THU0373 : SECUKINUMAB DOSE ESCALATION ON ACR RESPONSES IN ANTI-TUMOUR NECROSIS FACTOR NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 FUTURE 4 AND FUTURE 5 STUDIES

Researchers

Presenter

  • P. Emery

Principal Investigators

  • M. ?stergaard

  • L. C. Coates

  • A. Deodhar

  • E. Quebe-Fehling

  • P. Pellet

  • L. Pricop

  • C. Gaillez

  • F. Van den Bosch

Medical Centers

  • University of Leeds, Leeds, United Kingdom

  • BRIC, Copenhagen University, Copenhagen, Denmark

  • University of Oxford, Oxford, United Kingdom

  • Oregon Health & Science University, Portland, United States of America

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceuticals Corporation, US HEOR, East Hanover, United States of America

  • Ghent University Hospital, Ghent, Belgium

  • Inflammation Research Center, Ghent University - VIB, Gent, Belgium

Locations

  • United Kingdom

  • Denmark

  • United States

  • Switzerland

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Dose Escalation

Phase

  • III

Study Id's

  • NCT02294227

  • NCT02404350

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved